Pancreatic Cancer Research

ResearcherWhitehead Institute for Biomedical ResearchActive in the last 2 years

Tobiloba E. Oni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6916-3380; OpenAlex author ID A5003680800. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.01.756025↗
  2. Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology. Co-author DOI 10.1038/s12276-024-01378-w↗
  3. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. First author DOI 10.1073/pnas.2016904118↗
  4. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  5. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  6. Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models Co-author DOI 10.1101/2020.09.10.292193↗
  7. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  8. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  9. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/2159-8290.cd-18-0710↗
  10. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  11. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Arthur Tuveson · 9 shared papers, 2015–2021 · strength 0.70
  2. Youngkyu Park · 8 shared papers, 2015–2021 · strength 0.61
  3. Chang‐Il Hwang · 5 shared papers, 2015–2025 · strength 0.52
  4. Mariano Ponz‐Sarvisé · 4 shared papers, 2015–2025 · strength 0.44
  5. Vincenzo Corbo · 4 shared papers, 2015–2025 · strength 0.44
  6. Daniel Öhlund · 4 shared papers, 2015–2025 · strength 0.44
  7. Giulia Biffi · 6 shared papers, 2015–2021 · strength 0.44
  8. Ela Elyada · 5 shared papers, 2015–2021 · strength 0.35
  9. Hao Yuan · 4 shared papers, 2015–2021 · strength 0.30
  10. Jihao Xu · 1 shared paper, 2025 · strength 0.28
  11. Kenneth H. Yu · 4 shared papers, 2015–2020 · strength 0.26
  12. Lindsey A. Baker · 4 shared papers, 2015–2020 · strength 0.24
  13. Dannielle D. Engle · 4 shared papers, 2015–2019 · strength 0.22
  14. Hervé Tiriac · 4 shared papers, 2015–2019 · strength 0.22
  15. Brinda Alagesan · 3 shared papers, 2015–2021 · strength 0.22
  16. Jonathan M. DeLiberty · 1 shared paper, 2026 · strength 0.21
  17. Timothy Paul Heffernan · 1 shared paper, 2026 · strength 0.21
  18. João A. Paulo · 1 shared paper, 2026 · strength 0.21
  19. Brendan D. Parent · 1 shared paper, 2026 · strength 0.21
  20. Andrew J. Aguirre · 1 shared paper, 2026 · strength 0.21
  21. Clint A. Stalnecker · 1 shared paper, 2026 · strength 0.21
  22. Joseph Douglas Mancias · 1 shared paper, 2026 · strength 0.21
  23. Ralph H. Hruban · 3 shared papers, 2015–2020 · strength 0.18
  24. Iok In Christine Chio · 3 shared papers, 2015–2019 · strength 0.15
  25. Michael Goggins · 2 shared papers, 2019–2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.